inclusion criteria: 1. male and female patients aged ≥ 18 years to 50 years old, who recently admitted as in-patients and have not received any standard of care yet, with covid-19 confirmed by pcr with mild to moderate symptoms. 2. female subjects of child-bearing age agree to take effective contraceptive measures during the study until seven days of the last oral medication of study product; 3. willing to receive a random assignment to any designated treatment group and not participating in another study at the same time; 4. willing for not using any other immunomodulator or treatment that might bias the study 5. patient willing to provide informed consent.

inclusion criteria: 1. male and female patients aged ≥ 18 years to 50 years old, who recently admitted as in-patients and have not received any standard of care yet, with covid-19 confirmed by pcr with mild to moderate symptoms. 2. female subjects of child-bearing age agree to take effective contraceptive measures during the study until seven days of the last oral medication of study product; 3. willing to receive a random assignment to any designated treatment group and not participating in another study at the same time; 4. willing for not using any other immunomodulator or treatment that might bias the study 5. patient willing to provide informed consent.

inclusion criteria: male and female patients aged ≥ 18 years to 50 years old, who recently admitted as in-patients and have not received any standard of care yet, with covid-19 confirmed by pcr with mild to moderate symptoms. female subjects of child-bearing age agree to take effective contraceptive measures during the study until seven days of the last oral medication of study product; willing to receive a random assignment to any designated treatment group and not participating in another study at the same time; willing for not using any other immunomodulator or treatment that might bias the study patient willing to provide informed consent.

inclusion criteria: male and female patients aged ≥ 18 years to 50 years old, who recently admitted as in-patients and have not received any standard of care yet, with covid-19 confirmed by pcr with mild to moderate symptoms. female subjects of child-bearing age agree to take effective contraceptive measures during the study until seven days of the last oral medication of study product; willing to receive a random assignment to any designated treatment group and not participating in another study at the same time; willing for not using any other immunomodulator or treatment that might bias the study patient willing to provide informed consent.

inclusion criteria: 1. male and female patients aged ≥ 18 years to 50 years old, who recently admitted as in-patients and have not received any standard of care yet, with covid-19 confirmed by pcr with mild to moderate symptoms. 2. female subjects of child-bearing age agree to take effective contraceptive measures during the study until seven days of the last oral medication of study product; 3. willing to receive a random assignment to any designated treatment group and not participating in another study at the same time; 4. willing for not using any other immunomodulator or treatment that might bias the study 5. patient willing to provide informed consent.

inclusion criteria: 1. male and female patients aged ≥ 18 years to 50 years old, who recently admitted as in-patients and have not received any standard of care yet, with covid-19 confirmed by pcr with mild to moderate symptoms. 2. female subjects of child-bearing age agree to take effective contraceptive measures during the study until seven days of the last oral medication of study product; 3. willing to receive a random assignment to any designated treatment group and not participating in another study at the same time; 4. willing for not using any other immunomodulator or treatment that might bias the study 5. patient willing to provide informed consent.